Paliperidone Palmitate Flexible Dosing in Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

1,044

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2013

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone Palmitate

50 - 150 mg eq. every 30 days

Trial Locations (127)

Unknown

Salzburg

Brussels

Dave

Diest

Kruishoutem

Liège

Melle

Roeselare

Sint-Denijs-Westrem

Tournai

Rijeka

Zagreb

Aalborg

København V

Randers

Tallinn

Bar-le-Duc

Bron

Clermont-Ferrand

Dax

Dijon

Dole

Lille

Limoges

Montpellier

Nîmes

Paris

Saint-Nazaire

Saint-Priest-en-Jarez

Strasbourg

Villejuif

Bad Saarow

Berlin

Bielefeld

Bochum

Butzbach

Dresden

Gelsenkirchen

Greifswald

Hamburg

Heidelberg

Königsbrück

Mittweida

Oranienburg

Regensburg

Stralsund

Ulm

Westerstede

Würzburg

Arta

Athens

Katerini

Thessaloniki

Thessalonikis

Budapest

Debrecen

Pécs

Pardesiyya

Ramat Gan

Tirat Hacarmel

Daugavpils

Jelgava

Liepāja

Riga

Sigulda

Strenči

Panevezys

Vilnius

Groningen

Almada

Angra do Heroísmo

Castelo Viegas

Coimbra

Lisbon

Porto

Alcorcón

Alicante

Barcelona

Burgos

Coslada

Elche

Madrid

Málaga

Palma de Mallorca

Sant Boi de Llobregat

Sant Joan d'Alacant

Santa Coloma de Gramenet

Vigo

Zamora

Zaragoza

Gothenburg

Lidingö

Malmo

Mölndal

Spånga

Upplands Vasby

Solothurn

Zurich

Ankara

Diyarbakır

Gaziantep

Istanbul

Izmir

Trabzon

Dnipro

Donetsk

Hlevakha

Ivano-Frankivsk

Kharkiv

Kiev

Lviv

Odesa

Poltava

Simferopol

Smila

Ternopil

Uzhhorod

Yevpatoria

Barnet

Birmingham

Cambridge

Coventry

Darlington

Lincoln

London

Prescott

Stoke-on-Trent

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY